Last updated: October 1, 2023
Sponsor: Oman Medical Speciality Board
Overall Status: Active - Recruiting
Phase
4
Condition
Low Blood Sodium (Hyponatremia)
Treatment
salbutamol
Insulin regular
Dextrose 50
Clinical Study ID
NCT06036823
MREC #2779
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Hyperkalemia patients with lab potassium levels equal to or more than 5.5 mEq/L (≥ 5.5mEq/L)+.
- Adult: age 18 years or more.
- Agreed to participate in the study.
- If an investigator decides to start anti-hyperkalemia medications based on theVBG/ABG patient can be enrolled but if the main laboratory value is less than 5.5mEq/L patients will be excluded
Exclusion
Exclusion Criteria:
- Cardiac arrest
- Hyperglycemia with random blood sugar 20 mmol/L (13) or with acute diabeticcomplications like Diabetic Ketoacidosis / Hyperosmolar Hyperglycemic State.
- Hypoglycemia with random blood sugar (RBS) ≤ 3.89 mmol/l in Diabetic patients and lessthan 3 mmol/l in non-diabetic patients.
- Allergies for any medication in the protocol.
- Pregnancy.
- Hemolyzed potassium level as reported by the main lab.
- Hemolysis, Tumor lysis syndrome, or Rhabdomyolysis due to the ongoing release ofpotassium.
- Acidosis with a pH less than 7.1 will require Sodium bicarbonate (NaHO3).
- A patient who will need urgent Furosemide (Lasix), and or dialysis during the studyperiod of 2 hours.
- Refused to participate.
Study Design
Total Participants: 336
Treatment Group(s): 3
Primary Treatment: salbutamol
Phase: 4
Study Start date:
October 01, 2023
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
Sultan Qaboos University hospital
Seeb, Muscat 123
OmanActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.